An update from Zura Bio ( (ZURA) ) is now available.
Zura Bio has announced the launch of its global Phase 2 TibuSURE study, which will evaluate tibulizumab for treating systemic sclerosis in adults. This study represents a significant milestone for Zura Bio, as it addresses urgent unmet needs in the systemic sclerosis patient population, potentially enhancing treatment efficacy through its dual-pathway approach.
More about Zura Bio
Zura Bio is a clinical-stage, multi-asset immunology company focused on developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. The company is advancing a portfolio of therapeutic candidates, including tibulizumab, crebankitug, and torudokimab, aiming to address unmet needs in conditions like systemic sclerosis.
YTD Price Performance: -51.18%
Average Trading Volume: 401,001
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $148.9M
For detailed information about ZURA stock, go to TipRanks’ Stock Analysis page.